Retatrutide 20 mg vs 40 mg: pen contents
Compare Retatrutide 20 mg and 40 mg pen contents, product codes and label terms. Learn how total content differs from concentration and purity.
The Zynx blog
Retatrutide &
peptide research.
Clear explanations of the studies, the science and the formats. Explore the evidence, understand the terminology and follow the original sources.
How to check research peptide authenticity
Check research-peptide product codes, batch records and laboratory reports. Understand what verification establishes and how to investigate missing or mismatched details.
Read the articleMore from the blog
Retatrutide phase 2 vs phase 3: how to compare trial results
Compare the Retatrutide phase 2 trial with phase 3 TRIUMPH-1: study populations, 24-, 48- and 80-week endpoints, and why weight-loss headlines differ.
Retatrutide research
Start with the overview, then explore the questions answered by each study.
Retatrutide (Reta): what it is and trial results
What is Retatrutide (Reta, LY3437943)? Explore its GIP, GLP-1 and glucagon receptor activity and compare published phase 2 and phase 3 trial results.
Retatrutide phase 3 TRIUMPH-1 results: 80-week weight change
Read the 2026 TRIUMPH-1 phase 3 Retatrutide results: 25.0% mean body-weight reduction at 80 weeks versus 3.9% with placebo, and what the trial can and cannot show.
Retatrutide phase 2 trial: 24- and 48-week results
Retatrutide phase 2 trial explained: compare 24- and 48-week weight results, primary and secondary endpoints, study design and limitations.
Retatrutide fat loss: body-composition study explained
What does 26.1% fat-mass reduction mean? Explore Retatrutide DXA results in type 2 diabetes, placebo comparisons, lean mass and study limitations.
Retatrutide and liver fat: MRI trial results explained
Understand the 82.4% relative liver-fat reduction reported at 24 weeks in a Retatrutide trial, including MRI measurements, placebo and limitations.
Peptide science
The molecules, mechanisms and methods behind the research.
GLP-1, GIP and glucagon receptor agonists
Compare GLP-1, GIP and glucagon signalling, understand receptor agonists, and see how single, dual and triple agonists differ in published research.
Peptides, amino acids and protein synthesis
Understand peptide bonds, polypeptides, peptide structure and biological functions, with sources and links to Zynx's research library.
Peptide synthesis and sequencing explained
Compare peptide synthesis with peptide sequencing, and understand how analytical evidence relates to the identity of a research material.
BPC-157 research: tendon and blood-vessel studies explained
Read what selected BPC-157 tendon and angiogenesis studies measured, from rat-derived fibroblasts to animal models, and what they cannot establish in people.
Reading research material information
Understand analytical reports, traceability and the context of a listing.
How to read a peptide certificate of analysis (CoA)
A practical peptide CoA checklist: match the batch, read identity and HPLC results, distinguish purity from content, and check exactly what was tested.
Peptide purity vs content: HPLC and LC-MS explained
Understand why HPLC purity, LC-MS identity, peptide content and powder weight differ. Read a worked example and learn which result answers which question.
Research peptides in Europe: the Zynx approach
Discover Zynx's Germany-based laboratory and European research focus. Explore compound information, published papers, documentation and delivery destinations.
Understand the format
What makes a dual-chamber pen different?
Explore the physical format, see the chamber illustration and understand how cartridges, pens and vials differ.
Read the dual-chamber pen guideAbout these articles
Zynx publishes educational explanations of selected scientific and technical sources. Articles link to the original evidence and distinguish study findings from product information. They are not systematic reviews or personal medical advice.
Looking for the papers themselves? Browse the original study records. To suggest a correction or a newer source, contact Zynx.